We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$5.12B
1-Year Est. Return
314.02%
This Fund
S&P 500
This Quarter
Est. Return
+10.9%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.81B
AUM Growth
+$244M
(+6.8%)
Cap. Flow
-$21.2M
Cap. Flow
% of AUM
-0.56%
Top 10 Holdings %
Top 10 Hldgs %
49.66%
Holding
160
New
23
Increased
21
Reduced
32
Closed
35
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Verrica Pharmaceuticals
VRCA
|
+$66.8M |
| 2 |
MeiraGTx Holdings
MGTX
|
+$63.1M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
+$56.2M |
| 4 |
Intuitive Surgical
ISRG
|
+$41.2M |
| 5 |
KDMN
Kadmon Holdings, Inc.
KDMN
|
+$31.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ABMD
Abiomed Inc
ABMD
|
+$107M |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$47.9M |
| 3 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
+$34.2M |
| 4 |
AnaptysBio
ANAB
|
+$24.7M |
| 5 |
Agios Pharmaceuticals
AGIO
|
+$20.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.91% |
| 2 | Industrials | 0.65% |
| 3 | Consumer Discretionary | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Neurocrine Biosciences
NBIX
$18.2B
| $463M | 12.14% |
4,715,250
-46,739
| -1% | -$4.18M |
|
|
FOLD
2
DELISTED
Amicus Therapeutics
FOLD
| $313M | 8.2% |
20,024,424
| – | – |
|
|
GBT
3
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $218M | 5.72% |
4,828,910
-160,156
| -3% | -$7.29M |
|
|
4
Alnylam Pharmaceuticals
ALNY
$38.3B
| $182M | 4.77% |
1,846,911
+566,109
| +44% | +$56.2M |
|
|
ZGNX
5
DELISTED
Zogenix, Inc.
ZGNX
| $175M | 4.6% |
3,970,357
| – | – |
|
|
LJPC
6
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $126M | 3.3% |
4,313,611
| – | – |
|
|
BHVN
7
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $108M | 2.84% |
2,743,647
-183,802
| -6% | -$5.83M |
|
|
DOVA
8
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
| $93.5M | 2.45% |
3,125,851
+344,874
| +12% | +$9.39M |
|
9
Iovance Biotherapeutics
IOVA
$2.04B
| $74.9M | 1.96% |
5,852,202
-310,000
| -5% | -$4.53M |
|
|
XLRN
10
DELISTED
Acceleron Pharma
XLRN
| $74.1M | 1.94% |
1,528,205
+11,946
| +0.8% | +$435K |
|
11
Ascendis Pharma A/S
ASND
$16.5B
| $71.4M | 1.87% |
1,072,647
+90,000
| +9% | +$5.92M |
|
|
12
Verrica Pharmaceuticals
VRCA
$89M
| $67.3M | 1.76% |
+341,041
| New | +$66.8M |
|
13
Regenxbio
RGNX
$616M
| $62.2M | 1.63% |
867,106
-14,000
| -2% | -$669K |
|
|
BPMC
14
DELISTED
Blueprint Medicines
BPMC
| $61M | 1.6% |
961,147
-69,287
| -7% | -$5.51M |
|
|
ALBO
15
DELISTED
Albireo Pharma Inc
ALBO
| $60.5M | 1.59% |
1,704,330
| – | – |
|
|
ALXN
16
DELISTED
Alexion Pharmaceuticals
ALXN
| $57.5M | 1.51% |
463,450
-410,000
| -47% | -$47.9M |
|
17
Travere Therapeutics
TVTX
$5.17B
| $57.4M | 1.5% |
3,212,871
| – | – |
|
18
Merit Medical Systems
MMSI
$4.82B
| $55.4M | 1.45% |
1,082,013
+37,000
| +4% | +$1.83M |
|
19
uniQure
QURE
$2.75B
| $54.6M | 1.43% |
1,444,628
+50,000
| +4% | +$1.6M |
|
|
MYOK
20
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $54.1M | 1.42% |
1,089,169
+254,490
| +30% | +$12.3M |
|
|
21
MeiraGTx Holdings
MGTX
$1.08B
| $53.9M | 1.41% |
+4,703,398
| New | +$63.1M |
|
|
KDMN
22
DELISTED
Kadmon Holdings, Inc.
KDMN
| $52.5M | 1.38% |
13,165,746
+8,000,000
| +155% | +$31.2M |
|
|
QTNT
23
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $52.1M | 1.36% |
162,076
+11,250
| +7% | +$2.63M |
|
|
CORI
24
DELISTED
Corium International, Inc.
CORI
| $50.9M | 1.34% |
6,357,133
| – | – |
|
|
25
Intuitive Surgical
ISRG
$127B
| $47.8M | 1.25% |
300,000
+270,000
| +900% | +$41.2M |
|
Similar funds
BG
TAM
CIA
AC
EIC
CIC
CS
NC
Perceptive Advisors's Q2 2018 Portfolio in Review
As of Q2 2018, Perceptive Advisors held 160 positions worth $3.81B, up 6.8% from $3.57B the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Perceptive Advisors's Q2 2018 filing shows 23 new, 21 increased, 32 reduced and 35 closed positions. Its largest new stake was Verrica Pharmaceuticals: 341,041 shares worth $67.3M. The largest sale was Abiomed Inc, an estimated $107M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 96% a quarter earlier, followed by Industrials and Consumer Discretionary.
- Perceptive Advisors's largest Q2 2018 buy was Verrica Pharmaceuticals: 341,041 shares worth $67.3M.
- Perceptive Advisors added most to Alnylam Pharmaceuticals in Q2 2018, an estimated $56.2M increase.
- Perceptive Advisors's biggest Q2 2018 reduction was Abiomed Inc, cutting an estimated $107M.
- Perceptive Advisors fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $34.2M.
- Perceptive Advisors's ten largest holdings make up 50% of its $3.81B portfolio in Q2 2018.
- Perceptive Advisors opened 23 new positions and closed 35 in Q2 2018.
- Perceptive Advisors's portfolio value rose 6.8% quarter-over-quarter to $3.81B.
Based on Perceptive Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.